ClinicalTrials.gg
CompletedNCT02924337Updated Feb 10, 2017

Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

A Phase 1 interventional study of Placebo and Imeglimin in Qt Interval, Variation in, sponsored by Poxel SA. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-10.

Sponsored by Poxel SA · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effect of a single therapeutic dose and a single supra-therapeutic dose of imeglimin on the QT/QTc interval

02

Conditions studied

  • Qt Interval, Variation in

Keywords

  • QT/QTC interval
  • Hypoglycemic Agents
  • Imeglimin
  • Healthy Volunteers
03

In context

Lead sponsor

Poxel SA is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy volunteers
  • between 18.5 and 29.9 kg/m2
  • weighing between 55 and 95 kg
  • willing to use reliable
  • able to give fully informed written consent.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating woman, or sexually active woman of not using highly effective
  • abnormal medical history, surgery or concurrent medical condition; acute or chronic illness
  • clinically significant /QTc interval prolongation at Baseline
  • history of drug-induced or risk factors for Torsade de Pointes
  • any to moxifloxacin
  • severe adverse reaction to any drug or sensitivity to the trial medication or its components
  • significant food allergy; use of vitamins, herbal medicines, prescription or over-the-counter medication (with the exception of paracetamol [acetaminophen] and oral contraceptives for women) within 20 days or 6 half-lives before first dose of trial medication
  • participation in other clinical trials of unlicensed or prescription medicines, or loss of more than 400 mL blood, within the 3 months before first dose of trial medication
  • drug or alcohol abuse; smoking of more than 5 cigarettes, 1 cigars or 1 pipes daily
  • regular consumption of more than 5 cups of caffeinated drinks per day
  • positive test for hepatitis A, B \& C,
  • objection by a General Practitioner.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Imeglimin therapeutic dose

    Tablet, oral, single dose

    Drug: Imeglimin

  • Experimental
    Imeglimin supratherapeutic dose

    Tablet, oral, single dose

    Drug: Imeglimin

  • Placebo comparator
    Placebo

    Tablet, oral, single dose

    Drug: Placebo

  • Active comparator
    Moxifloxacin

    Tablet, oral, single dose (400 mg)

    Drug: Moxifloxacin

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in QTcF (deltaQTcF)

    Time frame: Up to 24 hours

07

Study locations

1 site
  • Hammersmith Medicines Research (HMR)
    London, United Kingdom
08

References and documents

Publications

  • Dubourg J, Perrimond-Dauchy S, Felices M, Bolze S, Voiriot P, Fouqueray P. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus. Eur J Clin Pharmacol. 2020 Oct;76(10):1393-1400. doi: 10.1007/s00228-020-02929-6. Epub 2020 Jun 18. PubMed 32556539 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2016
First posted
Oct 5, 2016
Start
Sep 2016
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Last update
Feb 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02924337
Lead sponsor
Poxel SA
Responsible party
Sponsor
First posted
Oct 5, 2016
Start date
Sep 2016
Primary completion
Dec 2016
Completion
Dec 2016
Last update
Feb 10, 2017

Study contacts

Julie Dubourg, MD
study director · Poxel SA
Pascale Fouqueray, MD, PhD
study director · Poxel SA
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imeglimin

Start the discussion